Literature DB >> 7456329

Angioimmunoblastic lymphadenopathy. Fine structure of the lymph nodes by correction of light and electron microscopical findings.

U Schnaidt, J Thiele, A Georgii.   

Abstract

Angioimmunoblastic lymphadenopathy was studied prospectively in 5 patients by correlation of light and electron microscopy of biopsy material obtained from lymph nodes, prior to any substantial therapy. The fine structure of this lymphoproliferative disease revealed various patterns of cellular composition: there was a predominance of lymphocytes, immunoblasts, epithelioid or plasmacytoid cells or mixed cellularity in the lymph nodes. The conspicuous vascular changes consisted or arborization of postcapillary venules, a thickening of the basement membranes and swelling of the endothelial cells. The remarkable eosinophilic or acidophilic debris-like interstitial and pericapillar deposits showed filamentous finely dispersed material containing wide-spacing collagen fibers intermingled with normal collagen, but no fragments of disintegrated cells. Two of these 5 patients developed malignant lymphomas of the Hodgkin-type after 13 months, and of the Non-Hodgkin-type after 7 months. At the time of first biopsy, however, no characteristic alteration of the fine structure of the lymph nodes disclosed evolution towards malignancy.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7456329     DOI: 10.1007/bf00430661

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histol        ISSN: 0340-1227


  33 in total

1.  Letter: Chromosomes in AILD.

Authors:  S L Volk; P L Monteleone; W A Knight
Journal:  N Engl J Med       Date:  1975-05-01       Impact factor: 91.245

2.  Angio-immunoblastic lymphadenopathy with dysproteinaemia.

Authors:  G Frizzera; E M Moran; H Rappaport
Journal:  Lancet       Date:  1974-06-01       Impact factor: 79.321

3.  Postvaccinial lymphadenitis. Hyperplasia of lymphoid tissue that simulates malignant lymphomas.

Authors:  R J Hartsock
Journal:  Cancer       Date:  1968-04       Impact factor: 6.860

4.  Angio-immunoblastic lymphadenopathy terminating as Hodgkin's disease.

Authors:  X Yataganas; C Papadimitriou; G Pangalis; D Loukopoulos; P Fessas; N Papacharalampous
Journal:  Cancer       Date:  1977-05       Impact factor: 6.860

5.  Angioimmunoblastic lymphadenopathy with dysproteinemia.

Authors:  L R Matz; J M Papadimitriou; J R Carroll; A L Barr; R L Dawkins; J M Jackson; R P Herrmann; B K Armstrong
Journal:  Cancer       Date:  1977-11       Impact factor: 6.860

6.  Immunoblastic sarcoma arising in child with immunoblastic lymphadenopathy.

Authors:  C B Howarth; C C Bird
Journal:  Lancet       Date:  1976-10-02       Impact factor: 79.321

7.  Banded structures in the connective tissue of lymphomas, lymphadenitis, and thymomas.

Authors:  F Mollo; G Monga
Journal:  Virchows Arch B Cell Pathol       Date:  1971

8.  [Rapidly debilitating disease with generalized lymphadenopathy, skin involvement and interstitial pulmonary infiltration (report of three cases)].

Authors:  O Haferkamp; W Schachenmayr; U R Kleeberg; A Wildfeuer; K Borowski; H Meister; N Konietzko; J Engels; K H Schrewe
Journal:  Dtsch Med Wochenschr       Date:  1975-02-21       Impact factor: 0.628

9.  Immunoblastic lymphadenopathy. Evolution into a malignant lymphoma with plasmacytoid features.

Authors:  R I Fisher; E S Jaffe; R C Braylan; J C Andersen; H K Tan
Journal:  Am J Med       Date:  1976-10       Impact factor: 4.965

10.  Post-capillary venules of the mouse lymphatic tissues with special reference to the distribution of their endothelial IgG.

Authors:  K J Syrjänen
Journal:  Exp Pathol (Jena)       Date:  1979
View more
  2 in total

1.  Angioimmunoblastic lymphadenopathy. Histopathology of bone marrow involvement.

Authors:  U Schnaidt; K F Vykoupil; J Thiele; A Georgii
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1980

2.  Lymph node hyalinisation in rheumatoid arthritis and systemic sclerosis.

Authors:  W G McCluggage; H Bharucha
Journal:  J Clin Pathol       Date:  1994-02       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.